https://www.newsworthy.ai/curated/oncotelic-therapeutics-highlighted-in-biomedwire-editorial-on-bi/202631289
Oncotelic Therapeutics Highlighted in BioMedWire Editorial on Biotech Valuation Shift as Drug...
Oncotelic Therapeutics is featured in a BioMedWire editorial that explores how advancing drug pipelines are reshaping biotech valuations under evolving...
biotech valuationtherapeuticshighlightedbiomedwireeditorial
https://www.sahmcapital.com/news/content/update-2-biotech-firm-odyssey-targets-810-million-valuation-in-us-ipo-2026-05-04
UPDATE 2-Biotech firm Odyssey targets $810 million valuation in US IPO
Adds details throughout May 4 (Reuters) - Biopharmaceutical company Odyssey Therapeutics said on Monday it is targeting a valuation of up to $809.9 million in...
us ipoupdatebiotechfirmodyssey
https://multiples.vc/public-comps/yili-chuannig-biotech-valuation-multiples
Yili Chuannig Biotech - Multiples.vc - Public Comps and Valuation Multiples
As of May 2026, Yili Chuannig Biotech has a market cap of $3B, revenue of $686M, revenue valuation multiple of 4.9x, and EBITDA valuation multiple of 14.4x.
public compsyilibiotechmultiplesvc
https://uk.marketscreener.com/quote/stock/SHENZHEN-YHLO-BIOTECH-CO--130552350/valuation/
Shenzhen YHLO Biotech Co., Ltd.: Valuation Ratios, Analysts' Forecasts - MarketScreener UK
Find analyst estimates regarding the valuation of Shenzhen YHLO Biotech Co., Ltd.. Enterprise Value, P/E Ratio, PEG, FCF, and many other Ratios. The entire...
shenzhenbiotechcoltdvaluation
https://research-information.bris.ac.uk/en/publications/the-stock-market-valuation-of-rampd-information-in-biotech-firms/
The stock market valuation of R&D information in biotech firms - University of Bristol
the stock marketvaluationinformationbiotechfirms
https://www.fiercebiotech.com/biotech/a-tale-two-bio-cities-moderna-tops-100b-valuation-matching-glaxosmithkline
A tale of 2 (bio) cities: Moderna tops $100B valuation, matching GlaxoSmithKline | Fierce Biotech
Jul 15, 2021 - Moderna's market cap hit $100 billion on Wednesday, briefly matching Big Pharma GlaxoSmithKline, as the pandemic cements the once controversial biotech into a...
talebiocitiesmodernatops
https://app.deepvalue.tech/news/12863-krys-nasdaq-krystal-biotech-q1-beats-but-valuation-already-priced-in
Krystal Biotech Q1 Beats, but Valuation Already Priced In | DeepValue Digest
May 5, 2026 - The Q1 beat affirms near-term execution but does not alter the fundamental risk-reward; valuation remains stretched as the core franchise matures and ex-U.S....
krystal biotechbeatsvaluationalreadypriced
https://biobostonconsulting.com/valuation-strategies-for-preclinical-biotech-companies/
Valuation Strategies for Preclinical Biotech Companies | BioBoston Consulting
Feb 12, 2026 - Learn how to value preclinical biotech companies. BioBoston Consulting helps early-stage startups build risk-adjusted, investor-ready valuation strategies.
biotech companiesvaluationstrategiespreclinicalconsulting